Hims & Hers stock in focus before open after weak Q1 outlook and BTIG downgrade
Hims & Hers Health shares fell 0.5% to $15.46 in late trading Tuesday after BTIG downgraded the stock to “neutral,” citing regulatory risks and slowing growth. The company faces scrutiny over compounded weight-loss drugs and a potential Department of Justice probe. First-quarter revenue guidance missed analyst expectations, triggering a 7% after-hours drop Monday.